Artrya Ltd (ASX:AYA) managing director John Barrington chats with Andrew Scott from Proactive about receiving regulatory approval for Salix Coronary Anatomy (SCA) product in the United Kingdom. Barrington discusses the size of this opportunity in the UK as well as growth potential in Europe. “Our business activities in the UK are advanced and Artrya is well-positioned to take advantage of the regulatory approval in this significant market."
Artrya says UK regulatory approval for Salix Coronary Anatomy product is landmark development
